Although pyridoxine has been used empirically for the prevention of capecitabine associated
hand-foot syndrome (HFS), its efficacy needs to be demonstrated in prospective controlled
trials. The investigators therefore performed a prospective randomized double-blind study to
determine whether pyridoxine 200 mg/day can prevent the development of HFS when given
concurrently with capecitabine. The investigators also tested the ability of pyridoxine to
treat primary occurrence of grade 2-3 HFS.